Moderna’s (MRNA) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Moderna (NASDAQ:MRNA) in a report released on Monday morning, Marketbeat Ratings reports.

MRNA has been the subject of a number of other reports. Bank of America reduced their target price on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research note on Tuesday, July 22nd. Cowen assumed coverage on shares of Moderna in a research report on Sunday, July 13th. They set a “hold” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Leerink Partners reduced their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research note on Friday, August 22nd. Finally, Barclays reduced their target price on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $39.93.

Moderna Price Performance

Shares of MRNA opened at $26.85 on Monday. Moderna has a one year low of $23.15 and a one year high of $57.69. The company has a 50-day moving average of $25.98 and a two-hundred day moving average of $27.11. The stock has a market cap of $10.49 billion, a price-to-earnings ratio of -3.57 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm’s revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Analysts anticipate that Moderna will post -9.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Moderna by 149.8% during the 1st quarter. GAMMA Investing LLC now owns 7,926 shares of the company’s stock valued at $225,000 after purchasing an additional 4,753 shares during the period. Janney Montgomery Scott LLC lifted its position in Moderna by 37.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 13,825 shares of the company’s stock valued at $392,000 after purchasing an additional 3,744 shares during the period. QRG Capital Management Inc. lifted its position in Moderna by 16.1% during the 1st quarter. QRG Capital Management Inc. now owns 8,274 shares of the company’s stock valued at $235,000 after purchasing an additional 1,150 shares during the period. Praxis Investment Management Inc. lifted its position in Moderna by 110.5% during the 1st quarter. Praxis Investment Management Inc. now owns 16,710 shares of the company’s stock valued at $474,000 after purchasing an additional 8,770 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Moderna during the 1st quarter valued at about $266,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.